Aciphex: Uses, Dosage, Side Effects
The active ingredient in ACIPHEX delayed-release tablets is rabeprazole Na, that could be a nucleon pump matter. it's a substituted benzimidazole best-known with chemicals as 2-[[[4-(3methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H–benzimidazole Na salt. it's associate degree formula of C18H20N3NaO3S and a mass of 381.42.
Rabeprazole Na could be a white to slightly yellowish-white solid. it's terribly soluble in water and wood alcohol, freely soluble in fermentation alcohol, chloroform, and ester and insoluble in ether and n-hexane. the steadiness of rabeprazole Na could be a perform of pH; it's quickly degraded in acid media, and is additional stable beneath alkaline conditions.
ACIPHEX is out there for oral administration as delayed-release, enteric-coated tablets containing twenty mg of rabeprazole Na.
Inactive ingredients of the twenty mg pill are wax, crospovidone, diacetylated monoglycerides, ethylcellulose, hydroxypropyl polyose, hypromellose phthalate, atomic number 12 stearate, mannitol, antifreeze, hydroxide, Na stearyl fumarate, talc, and pigment. Iron compound yellow is that the coloring agent for the pill coating. Iron compound red is that the ink pigment.
Generic Name: rabeprazole sodium
Healing Of Erosive Or lesion GERD In Adults
ACIPHEX delayed-release tablets are indicated for short (4 to eight weeks) treatment within the healing and symptomatic relief of erosive or lesion reflux unwellness (GERD). For those patients United Nations agency haven't well when eight weeks of treatment, a further 8-week course of ACIPHEX could also be thought-about.
Maintenance Of Healing Of Erosive Or lesion GERD In Adults
ACIPHEX delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of pyrosis symptoms in patients with erosive or lesion reflux unwellness (GERD Maintenance). Controlled studies don't extend on the far side twelve months.
Treatment Of Symptomatic GERD In Adults
ACIPHEX delayed-release tablets are indicated for the treatment of daytime and nighttime pyrosis and alternative symptoms related to GERD in adults for up to four weeks.
Healing Of small intestine Ulcers In Adults
ACIPHEX delayed-release tablets are indicated for short (up to four weeks) treatment within the healing and symptomatic relief of small intestine ulcers. Most patients heal inside four weeks.
Helicobacter Pylori wipeout to cut back the danger Of peptic ulcer repeat In Adults
ACIPHEX delayed-release tablets, together with Trimox and clarithromycin as a 3 drug programme, are indicated for the treatment of patients with H. pylori infection and peptic ulcer unwellness (active or history inside the past five years) to eradicate H. pylori. wipeout of H. pylori has been shown to cut back the danger of peptic ulcer repeat.
In patients United Nations agency fail medical aid, status testing ought to be done. If resistance to clarithromycin is incontestable or status testing isn't attainable, different antimicrobial medical aid ought to be instituted.
Treatment Of Pathological Hypersecretory Conditions, together with Zollinger-Ellison syndrome In Adults
ACIPHEX delayed-release tablets are indicated for the long-run treatment of pathological hypersecretory conditions, together with Zollinger-Ellison syndrome.
Treatment Of Symptomatic GERD In Adolescent Patients twelve Years old And Older
ACIPHEX delayed-release tablets are indicated for the treatment of symptomatic GERD in adolescents twelve years old and on top of for up to eight weeks.
Table one shows the suggested indefinite quantity of ACIPHEX delayed-release tablets in adults and adolescent patients twelve years old and older. the utilization of ACIPHEX delayed-release pills isn't suggested to be used in paediatric patients one year to but twelve years old as a result of very cheap accessible tablet strength (20 mg) exceeds the recommended dose for these patients. Use another rabeprazole formulation for paediatric patients one year to but twelve years old.
Aciphex Side Effects:
The following serious adverse reactions are represented below et al. in labeling:
Acute opening kidney disease.
Clostridium difficile-Associated symptom.
Cutaneous and general autoimmune disease.
Cyanocobalamin (Vitamin B-12) Deficiency.